The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Issue 2 (17th December 2012)

• Record Type: Journal Article
• Authors: Smith, M.; Blaker, P.; Patel, C.; Marinaki, A.; Arenas, M.; Escuredo, E.; Anderson, S.; Irving, P.; Sanderson, J.
• Is Part Of: International journal of clinical practice. Volume 67:Issue 2(2013)
• Page Start: 161
• Page End: 169
• Publication Date: 2012-12-17
• Subjects: Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.12039
• Languages: English
• ISSNs: 1368-5031

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Summary</title> <p> <bold>Background: </bold> Thioguanine nucleotides (TGNs) are the active product of thiopurine metabolism. Levels have been correlated with effective clinical response. Nonetheless, the value of TGN monitoring in clinical practice is debated. We report the influence of introducing TGN monitoring into a large adult inflammatory bowel disease (IBD) clinic.</p> <p> <bold>Patients and methods: </bold> Patients with IBD undergoing TGN monitoring were identified from Purine Research Laboratory records. Whole blood TGNs and methylated mercaptopurine nucleotides were hydrolysed to the base and measured using HPLC. Clinical and laboratory data were obtained retrospectively.</p> <p> <bold>Results: </bold> One hundred and eighty‐nine patients with 608 available TGN results were identified. In non‐responders, TGNs directed treatment change in 39/53 patients. When treatment was changed as directed by TGN, 18/20 (90%) improved vs. 7/21 (33%) where the treatment decision was not TGN‐directed, p < 0.001. Where treatment change was directed at optimisation of thiopurine therapy, 14/20 achieved steroid‐free remission at 6 months vs. 3/10 where the TGN was ignored, (p = 0.037).</p> <p>Six per cent of patients were non‐adherent, 25% under‐dosed and 29% over‐dosed by TGN. Twelve per cent of patients predominantly methylated thiopurines, this group had low TGN levels and high risk of hepatotoxicity. In responders, adherence and dosing issues were identified and TGN‐guided dose‐reduction was possible without precipitating relapse.</p> <p>Mean cell volume (MCV), white blood cell count (WBC) and lymphocyte counts were not adequate surrogate markers. MCV/WBC ratio correlated with clinical response, but was less useful than TGN for guiding clinical decisions.</p> <p> <bold>Conclusions: </bold> Monitoring TGNs enables thiopurine therapy to be optimised and individualised, guiding effective treatment decisions and improving clinical outcomes.</p> </abstract>